(Q42710598)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Che-Ming Teng

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Hsueh-Yun Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mei-Jung Lai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Han-Li Huang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yi-Ling Hsieh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yi-Min Liu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Teng-Kuang Yeh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yu-Hsuan Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Samir Mehndiratta

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jing-Ping Liou

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

20 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1248-1254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

Unraveling the epigenetic code of cancer for therapy

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase inhibitors: from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Role of epigenetics in inflammation-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201300201

21 January 2018

Identifiers

DOI

10.1002/CBIC.201300201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788254%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference